Topiramate, pseudotumor cerebri, weight-loss and glaucoma

An ophthalmologic perspective

Patrick Alore, Walter Jay, Mícheál Macken*

*Corresponding author for this work

Research output: Contribution to journalShort survey

21 Citations (Scopus)

Abstract

Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.

Original languageEnglish (US)
Pages (from-to)15-17
Number of pages3
JournalSeminars in Ophthalmology
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Pseudotumor Cerebri
Glaucoma
Weight Loss
Carbonic Anhydrase Inhibitors
Angle Closure Glaucoma
Anorexia
Migraine Disorders
Epilepsy
Therapeutics
topiramate

Keywords

  • Glaucoma
  • Pseudotumor cerebri
  • Topiramate
  • Weight loss

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{3d5a51823e3e408a9201364a1394bd2a,
title = "Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective",
abstract = "Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.",
keywords = "Glaucoma, Pseudotumor cerebri, Topiramate, Weight loss",
author = "Patrick Alore and Walter Jay and M{\'i}che{\'a}l Macken",
year = "2006",
month = "1",
day = "1",
doi = "10.1080/08820530500509325",
language = "English (US)",
volume = "21",
pages = "15--17",
journal = "Seminars in Ophthalmology",
issn = "0882-0538",
publisher = "Informa Healthcare",
number = "1",

}

Topiramate, pseudotumor cerebri, weight-loss and glaucoma : An ophthalmologic perspective. / Alore, Patrick; Jay, Walter; Macken, Mícheál.

In: Seminars in Ophthalmology, Vol. 21, No. 1, 01.01.2006, p. 15-17.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Topiramate, pseudotumor cerebri, weight-loss and glaucoma

T2 - An ophthalmologic perspective

AU - Alore, Patrick

AU - Jay, Walter

AU - Macken, Mícheál

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.

AB - Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.

KW - Glaucoma

KW - Pseudotumor cerebri

KW - Topiramate

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=33646928897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646928897&partnerID=8YFLogxK

U2 - 10.1080/08820530500509325

DO - 10.1080/08820530500509325

M3 - Short survey

VL - 21

SP - 15

EP - 17

JO - Seminars in Ophthalmology

JF - Seminars in Ophthalmology

SN - 0882-0538

IS - 1

ER -